¼¼°èÀÇ ÆÄÁ¦Å¸(Perjeta) ½ÃÀå : ½ÃÀå ±Ô¸ð, Á¡À¯À² ¹× µ¿Çâ, ¾÷°è ºÐ¼®(À¯Çüº°, Á¦Ç°º°, ÀûÀÀÁõº°, À¯Åë ä³Îº°, Áö¿ªº°), ¿¹Ãø(2025-2034³â)
Perjeta Market Size, Share, & Industry Analysis Report: By Type, By Product (Monoclonal Antibody and Generic Drug), By Indication, By Distribution Channel, and By Region - Market Forecast, 2025-2034
Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é, Perjeta ½ÃÀå ±Ô¸ð´Â 2034³â±îÁö 71¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÅëÂû·Â°ú ¹Ì·¡ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.
ÆÛÁ¦Å¸´Â ¾Ï¼¼Æ÷ÀÇ ½ÅÈ£Àü´Þ °æ·Î¸¦ ÆÄ±«ÇÏ´Â HER2 Ç¥Àû ´ÜÀÏŬ·ÐÇ×ü Ä¡·áÁ¦·Î, ÃʸÂÃãÇü ÀÇ·á·ÎÀÇ ÀüȯÀÌ ÁøÇàµÊ¿¡ µû¶ó Á¾¾çÇÐ ½ÃÀå¿¡¼ Áö¼ÓÀûÀ¸·Î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â °³º° Á¾¾ç ÇÁ·ÎÆÄÀÏ¿¡ ¸Â´Â »ý¹°ÇÐÀû Á¦Á¦ÀÇ »ç¿ëÀ» °Á¶Çϰí ÀÖÀ¸¸ç, ÆÛÁ¦Å¸´Â HER2 ¾ç¼º Ä¡·á ¿ä¹ý¿¡¼ Áß¿äÇÑ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù. ÆÛÁ¦Å¸°¡ Á¦°øÇÏ´Â °íÁ¤¹Ð Ÿ°ÙÆÃÀº Àü½Å µ¶¼ºÀ» ÃÖ¼ÒÈÇÏ¸é¼ Ä¡·á È¿°ú¸¦ ³ôÀ̰í ȯÀÚº° ¸ÂÃã ¾Ï Ä¡·á¸¦ ÁöÇâÇÏ´Â ±¤¹üÀ§ÇÑ ¿òÁ÷ÀÓ°ú ÀÏÄ¡ÇÕ´Ï´Ù. Ä¡·á ÆÐ·¯´ÙÀÓÀÌ ÁøÈÇÔ¿¡ µû¶ó ÀÇ·áÁøÀº ºÐÀÚÀû Á¤¹Ðµµ¿Í ÃøÁ¤ °¡´ÉÇÑ ÀÓ»ó °á°ú¸¦ Á¦°øÇÏ´Â Ä¡·á¹ýÀ» Á¡Á¡ ´õ ¿ì¼±¼øÀ§¿¡ µÎ°í ÀÖ½À´Ï´Ù.
Ä¡·á È¿°ú¸¦ ÃÖÀûÈÇϱâ À§ÇÑ º´¿ë¿ä¹ýÀÇ ÅëÇÕÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ¾÷°è ¼ºÀåÀÇ ±âȸ·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÆÛÁ¦Å¸´Â ÀϹÝÀûÀ¸·Î Æ®¶ó½ºÅõÁÖ¸¿ ¹× ÈÇпä¹ý°ú º´¿ëÅõ¿©ÇÏ´Â °ÍÀÌ ÀϹÝÀûÀ̸ç, ½Ã³ÊÁö È¿°ú¸¦ ¹ßÈÖÇÏ¿© Á¾ÇÕÀûÀÎ HER2 ¾ç¼º À¯¹æ¾Ï °ü¸®ÀÇ Çٽɿä¹ýÀ¸·Î äÅõǰí ÀÖ½À´Ï´Ù. ÀÌ º´¿ë Àü·«Àº HER2 ¼ö¿ëü Â÷´ÜÀ» °³¼±Çϰí, Áúº´ ÁøÇàÀÇ À§ÇèÀ» °¨¼Ò½Ã۸ç, ȯÀÚÀÇ »ýÁ¸À² Çâ»ó¿¡ ±â¿©ÇÕ´Ï´Ù. ÀÓ»ó¿¡¼ ´ÙÁ¦ º´¿ë¿ä¹ý¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ °ËÅä´Â °ß°íÇϰí Áö¼ÓÀûÀÎ ¹ÝÀÀÀ» º¸ÀÌ´Â Áøº¸µÈ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä¸¦ °Á¶Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ÆÛÁ¦Å¸°¡ Çö´ë Á¾¾çÇÐ Ä¡·á¿¡¼ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ½À» °Á¶Çϰí ÀÖ½À´Ï´Ù.
ÆÄÁ¦Å¸ ½ÃÀå : ºÐ¼® °³¿ä
Á¦Ç°º°·Î´Â HER2 ¾ç¼º À¯¹æ¾Ï Ä¡·á¿¡¼ ´ÜÀÏŬ·ÐÇ×üÀÇ Á¤È®ÇÑ Ç¥ÀûÈ ±âÀü°ú ÀÔÁõµÈ ÀÓ»óÀû È¿°ú·Î ÀÎÇØ ´ÜÀÏŬ·ÐÇ×ü ºÎ¹®ÀÌ 2024³â Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
ÆÇ¸Å ä³Îº°·Î´Â µðÁöÅÐ ÀÇ·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ¼±È£µµ º¯È¿Í Àü¹® ÀǾàǰ¿¡ ´ëÇÑ Æí¸®ÇÑ Á¢±Ù¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ¿Â¶óÀÎ ¾à±¹ ºÐ¾ß°¡ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼ºÀå·üÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
2024³â ºÏ¹Ì´Â Á¤±³ÇÑ ÀÇ·á ½Ã½ºÅÛ, ³ôÀº Áúº´ ÀνÄ, ÷´Ü ¾Ï Ä¡·áÁ¦ÀÇ Æø³ÐÀº °¡¿ë¼º µî¿¡ ÈûÀÔ¾î ¾÷°è ¼±µÎ¸¦ Â÷ÁöÁöÇß½À´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÆÛÁ¦Å¸ ½ÃÀåÀº °Ç° ÀÎ½Ä Áõ°¡, ¾Ï °¨Áö ±â¼úÀÇ ¹ßÀü, ¾Ï Ä¡·á ½Ã¼³¿¡ ´ëÇÑ ÅõÀÚ È®´ë µîÀ» ¹è°æÀ¸·Î ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
½ÃÀå ÁÖ¿ä ±â¾÷À¸·Î´Â F. Hoffmann-La Roche Ltd., Biocon, Samsung Bioepis, Pfizer Inc., Genentech, Inc. µîÀÌ ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼·Ð
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ºÐ¼® ¹æ¹ý
Á¦4Àå ¼¼°èÀÇ ÆÄÁ¦Å¸ ½ÃÀå ÀλçÀÌÆ®
- ½ÃÀå ÇöȲ
- ÆÄÁ¦Å¸ ½ÃÀå ¿ªÇÐ
- ¼ºÀå ÃËÁø¿äÀΰú ±âȸ
- ¼ºÀå ¾ïÁ¦¿äÀΰú °úÁ¦
- PESTLE ºÐ¼®
- ÆÄÁ¦Å¸ ½ÃÀå µ¿Çâ
- ¹ë·ùüÀÎ ºÐ¼®
Á¦5Àå ¼¼°èÀÇ ÆÄÁ¦Å¸ ½ÃÀå : Á¦Ç°º°
- ÁÖ¿ä ºÐ¼® °á°ú
- ¼·Ð
- ´ÜÀÏŬ·ÐÇ×ü
- Á¦³×¸¯ ÀǾàǰ
Á¦6Àå ¼¼°èÀÇ ÆÄÁ¦Å¸ ½ÃÀå : ÀûÀÀÁõº°
- ÁÖ¿ä ºÐ¼® °á°ú
- ¼·Ð
- Á¶±â À¯¹æ¾Ï
- ÀüÀ̼º À¯¹æ¾Ï
Á¦7Àå ¼¼°èÀÇ ÆÄÁ¦Å¸ ½ÃÀå : À¯Åë ä³Îº°
- ÁÖ¿ä ºÐ¼® °á°ú
- ¼·Ð
- º´¿ø ¾à±¹
- Àü¹® ¾à±¹
- ¿Â¶óÀÎ ¾à±¹
Á¦8Àå ¼¼°èÀÇ ÆÄÁ¦Å¸ ½ÃÀå : Áö¿ªº°
- ÁÖ¿ä ºÐ¼® °á°ú
- ¼·Ð
- ÆÄÁ¦Å¸ ½ÃÀå ºÐ¼® : Áö¿ªº°(2020-2034³â)
- ºÏ¹Ì
- ºÏ¹Ì : Á¦Ç°º°(2020-2034³â)
- ºÏ¹Ì : ÀûÀÀÁõº°(2020-2034³â)
- ºÏ¹Ì : À¯Åë ä³Îº°(2020-2034³â)
- ¹Ì±¹
- ij³ª´Ù
- À¯·´
- À¯·´ : Á¦Ç°º°(2020-2034³â)
- À¯·´ : ÀûÀÀÁõº°(2020-2034³â)
- À¯·´ : À¯Åë ä³Îº°(2020-2034³â)
- ¿µ±¹
- ÇÁ¶û½º
- µ¶ÀÏ
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ³×´ú¶õµå
- ·¯½Ã¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¾Æ½Ã¾ÆÅÂÆò¾ç : Á¦Ç°º°(2020-2034³â)
- ¾Æ½Ã¾ÆÅÂÆò¾ç : ÀûÀÀÁõº°(2020-2034³â)
- ¾Æ½Ã¾ÆÅÂÆò¾ç : À¯Åë ä³Îº°(2020-2034³â)
- Áß±¹
- Àεµ
- ¸»·¹À̽þÆ
- ÀϺ»
- Àεµ³×½Ã¾Æ
- Çѱ¹
- È£ÁÖ
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : Á¦Ç°º°(2020-2034³â)
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ÀûÀÀÁõº°(2020-2034³â)
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : À¯Åë ä³Îº°(2020-2034³â)
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
- À̽º¶ó¿¤
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ¶óƾ¾Æ¸Þ¸®Ä«
- ¶óƾ¾Æ¸Þ¸®Ä« : Á¦Ç°º°(2020-2034³â)
- ¶óƾ¾Æ¸Þ¸®Ä« : ÀûÀÀÁõº°(2020-2034³â)
- ¶óƾ¾Æ¸Þ¸®Ä« : À¯Åë ä³Îº°, 2020³â-2034³â
- ¸ß½ÃÄÚ
- ºê¶óÁú
- ¾Æ¸£ÇîÆ¼³ª
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
Á¦9Àå °æÀï ±¸µµ
- »ç¾÷ È®´ë ¹× ±â¾÷ Àμö ºÐ¼®
- Á¦ÈÞ/Çù¾÷/ÇÕÀÇ/°ø°³
Á¦10Àå ±â¾÷ °³¿ä
- F. Hoffmann-La Roche Ltd
- Biocon
- Samsung Bioepis.
- Pfizer Inc.
- Genentech, Inc.
- Dr. Reddy's Laboratories Ltd.
- CELLTRION INC.
LSH
The perjeta market size is expected to reach USD 7.13 billion by 2034, according to a new study by Polaris Market Research. The report "Perjeta Market Share, Size, & Industry Analysis Report: By Type, By Product (Monoclonal Antibody and Generic Drug), By Indication, By Distribution Channel, and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Perjeta is a HER2-targeted monoclonal antibody therapy that disrupts cancer cell signaling pathways, with a continuation to gain momentum in the oncology market amid a growing shift toward hyper personalized medicine. This trend highlights the use of biologic therapies tailored to individual tumor profiles, making Perjeta a critical component in HER2-positive treatment regimens. The precision targeting offered by Perjeta improves therapeutic efficacy while minimizing systemic toxicity, aligning with the broader movement toward customized, patient-specific cancer care. Healthcare providers are increasingly prioritizing therapies that offer molecular precision and measurable clinical outcomes as treatment paradigms evolve.
The increasing integration of combination therapies to optimize treatment effectiveness contributes to industry growth opportunities. Perjeta, commonly administered alongside trastuzumab and chemotherapy, has demonstrated synergistic benefits, driving its adoption as a cornerstone in comprehensive HER2-positive breast cancer management. This combination strategy improves the blockade of HER2 receptors and reduces disease progression risks, contributing to improved patient survival. The continued exploration of multi-agent regimens in clinical practice highlights the demand for advanced therapies that deliver robust, durable responses, reinforcing Perjeta's relevance in contemporary oncologic care.
Perjeta Market Report Highlights
In terms of product, the monoclonal antibodies segment accounted for a larger revenue share in 2024, owing to their precise targeting mechanism and demonstrated clinical effectiveness in HER2-positive breast cancer treatment.
Based on distribution channel, the online pharmacies segment is anticipated to register the fastest growth rate during the forecast period, driven by evolving consumer preferences toward digital healthcare solutions and the rising demand for convenient access to specialized medications.
In 2024, North America held the leading position in the industry, supported by its sophisticated healthcare systems, strong disease awareness, and broad availability of advanced cancer treatments.
The Asia Pacific Perjeta market is expected to expand at the most rapid pace during the forecast period, driven by increasing health consciousness, advancements in cancer detection technologies, and expanding investments in cancer care facilities.
A few global key market players include F. Hoffmann-La Roche Ltd; Biocon; Samsung Bioepis; Pfizer Inc.; Genentech, Inc.; Dr. Reddy's Laboratories Ltd.; and CELLTRION INC.
Polaris Market Research has segmented the Perjeta market report on the basis of type, application, end use, and region:
By Product Outlook (Revenue, USD Billion, 2020-2034)
Monoclonal Antibody
Generic Drug
By Indication Outlook (Revenue, USD Billion, 2020-2034)
Early Breast Cancer
Metastatic Breast Cancer
By Distribution Channel Outlook (Revenue, USD Billion, 2020-2034)
Hospital Pharmacies
Specialty Pharmacies
Online Pharmacies
By Regional Outlook (Revenue, USD Billion, 2020-2034)
North America
US
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Vietnam
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
3. Research Methodology
- 3.1. Overview
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Perjeta Market Insights
- 4.1. Perjeta Market - Market Snapshot
- 4.2. Perjeta Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising Prevalence of Chronic Diseases
- 4.2.1.2. Rapidly Growing Geriatric Population
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Lack of Skilled Labors
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Perjeta Market Trends
- 4.6. Value Chain Analysis
5. Global Perjeta Market, by Product
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Perjeta Market, by Product, 2020-2034 (USD billion)
- 5.3. Monoclonal Antibody
- 5.3.1. Global Perjeta Market, by Monoclonal Antibody, by Region, 2020-2034 (USD billion)
- 5.4. Generic Drug
- 5.4.1. Global Perjeta Market, by Generic Drug, by Region, 2020-2034 (USD billion)
6. Global Perjeta Market, by Indication
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Perjeta Market, by Indication, 2020-2034 (USD billion)
- 6.3. Early Breast Cancer
- 6.3.1. Global Perjeta Market, by Early Breast Cancer, by Region, 2020-2034 (USD billion)
- 6.4. Metastatic Breast Cancer
- 6.4.1. Global Perjeta Market, by Metastatic Breast Cancer, by Region, 2020-2034 (USD billion)
7. Global Perjeta Market, by Distribution Channel
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 7.3. Hospital Pharmacies
- 7.3.1. Global Perjeta Market, by Hospital Pharmacies, by Region, 2020-2034 (USD billion)
- 7.4. Specialty Pharmacies
- 7.4.1. Global Perjeta Market, by Specialty Pharmacies, by Region, 2020-2034 (USD billion)
- 7.5. Online Pharmacies
- 7.5.1. Global Perjeta Market, by Online Pharmacies, by Region, 2020-2034 (USD billion)
8. Global Perjeta Market, by Geography
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Perjeta Market Assessment, By Geography, 2020-2034 (USD billion)
- 8.3. Perjeta Market - North America
- 8.3.1. North America: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.3.2. North America: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.3.3. North America: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.3.4. Perjeta Market - U.S.
- 8.3.4.1. U.S.: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.3.4.2. U.S.: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.3.4.3. U.S.: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.3.5. Perjeta Market - Canada
- 8.3.5.1. Canada: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.3.5.2. Canada: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.3.5.3. Canada: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.4. Perjeta Market - Europe
- 8.4.1. Europe: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.4.2. Europe: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.4.3. Europe: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.4.4. Perjeta Market - UK
- 8.4.4.1. UK: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.4.4.2. UK: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.4.4.3. UK: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.4.5. Perjeta Market - France
- 8.4.5.1. France: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.4.5.2. France: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.4.5.3. France: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.4.6. Perjeta Market - Germany
- 8.4.6.1. Germany: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.4.6.2. Germany: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.4.6.3. Germany: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.4.7. Perjeta Market - Italy
- 8.4.7.1. Italy: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.4.7.2. Italy: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.4.7.3. Italy: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.4.8. Perjeta Market - Spain
- 8.4.8.1. Spain: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.4.8.2. Spain: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.4.8.3. Spain: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.4.9. Perjeta Market - Netherlands
- 8.4.9.1. Netherlands: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.4.9.2. Netherlands: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.4.9.3. Netherlands: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.4.10. Perjeta Market - Russia
- 8.4.10.1. Russia: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.4.10.2. Russia: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.4.10.3. Russia: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.4.11. Perjeta Market - Rest of Europe
- 8.4.11.1. Rest of Europe: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.4.11.2. Rest of Europe: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.4.11.3. Rest of Europe: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.5. Perjeta Market - Asia Pacific
- 8.5.1. Asia Pacific: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.5.2. Asia Pacific: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.5.3. Asia Pacific: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.5.4. Perjeta Market - China
- 8.5.4.1. China: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.5.4.2. China: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.5.4.3. China: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.5.5. Perjeta Market - India
- 8.5.5.1. India: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.5.5.2. India: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.5.5.3. India: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.5.6. Perjeta Market - Malaysia
- 8.5.6.1. Malaysia: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.5.6.2. Malaysia: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.5.6.3. Malaysia: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.5.7. Perjeta Market - Japan
- 8.5.7.1. Japan: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.5.7.2. Japan: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.5.7.3. Japan: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.5.8. Perjeta Market - Indonesia
- 8.5.8.1. Indonesia: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.5.8.2. Indonesia: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.5.8.3. Indonesia: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.5.9. Perjeta Market - South Korea
- 8.5.9.1. South Korea: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.5.9.2. South Korea: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.5.9.3. South Korea: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.5.10. Perjeta Market - Australia
- 8.5.10.1. Australia: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.5.10.2. Australia: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.5.10.3. Australia: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.5.11. Perjeta Market - Rest of Asia Pacific
- 8.5.11.1. Rest of Asia Pacific: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.5.11.2. Rest of Asia Pacific: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.5.11.3. Rest of Asia Pacific: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.6. Perjeta Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.6.2. Middle East & Africa: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.6.3. Middle East & Africa: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.6.4. Perjeta Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.6.4.2. Saudi Arabia: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.6.4.3. Saudi Arabia: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.6.5. Perjeta Market - UAE
- 8.6.5.1. UAE: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.6.5.2. UAE: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.6.5.3. UAE: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.6.6. Perjeta Market - Israel
- 8.6.6.1. Israel: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.6.6.2. Israel: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.6.6.3. Israel: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.6.7. Perjeta Market - South Africa
- 8.6.7.1. South Africa: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.6.7.2. South Africa: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.6.7.3. South Africa: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.6.8. Perjeta Market - Rest of Middle East & Africa
- 8.6.8.1. Rest of Middle East & Africa: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.6.8.2. Rest of Middle East & Africa: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.6.8.3. Rest of Middle East & Africa: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.7. Perjeta Market - Latin America
- 8.7.1. Latin America: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.7.2. Latin America: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.7.3. Latin America: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.7.4. Perjeta Market - Mexico
- 8.7.4.1. Mexico: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.7.4.2. Mexico: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.7.4.3. Mexico: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.7.5. Perjeta Market - Brazil
- 8.7.5.1. Brazil: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.7.5.2. Brazil: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.7.5.3. Brazil: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.7.6. Perjeta Market - Argentina
- 8.7.6.1. Argentina: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.7.6.2. Argentina: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.7.6.3. Argentina: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.7.7. Perjeta Market - Rest of Latin America
- 8.7.7.1. Rest of Latin America: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.7.7.2. Rest of Latin America: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.7.7.3. Rest of Latin America: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. F. Hoffmann-La Roche Ltd
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Biocon
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Samsung Bioepis.
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Pfizer Inc.
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Genentech, Inc.
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Dr. Reddy's Laboratories Ltd.
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. CELLTRION INC.
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development